In the current study, the efficacy of epalrestat for diabetic retinopathy/nephropathy was examined by re-analysis of the results of the Aldose Reductase Inhibitor–Diabetes Complications Trial, with consideration of the influence of patient background factors and severity of diabetic neuropathy. The gene discussed is AKR1B1; the disease is diabetic neuropathy.